Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery
This is not the latest version of this item. The latest version can be found here.

Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery

Thumbnail Image
Download
Name

nihms-1625422.pdf

Description
Accepted version
Size

2.77 MB

Format

Adobe PDF

Checksum (MD5)

a891ce7e8ad8f240b31b5f86d0f40da8

sword-2021-06-10T15:28:28.original.xml (130 B)
Original SWORD entry document
Author(s)
Barberio, Antonio E
•
Smith, Sean G
•
Correa, Santiago
•
Nguyen, Cathy
•
Nhan, Bang
•
Melo, Mariane
•
Tokatlian, Talar
•
Suh, Heikyung
•
Irvine, Darrell J
•
Hammond, Paula T
Date Issued
2020
Journal
ACS Nano
Publisher
American Chemical Society (ACS)
Citation
Barberio, Antonio E, Smith, Sean G, Correa, Santiago, Nguyen, Cathy, Nhan, Bang et al. 2020. "Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery." ACS Nano, 14 (9).
Version
Author's final manuscript
Abstract
© 2020 American Chemical Society. Although cytokine therapy is an attractive strategy to build a more robust immune response in tumors, cytokines have faced clinical failures due to toxicity. In particular, interleukin-12 has shown great clinical promise but was limited in translation because of systemic toxicity. In this study, we demonstrate an enhanced ability to reduce toxicity without affecting the efficacy of IL-12 therapy. We engineer the material properties of a NP to meet the enhanced demands for optimal cytokine delivery by using the layer-by-layer (LbL) approach. Importantly, using LbL, we demonstrate cell-level trafficking of NPs to preferentially localize to the cell's outer surface and act as a drug depot, which is required for optimal payload activity on neighboring cytokine membrane receptors. LbL-NPs showed efficacy against a tumor challenge in both colorectal and ovarian tumors at doses that were not tolerated when administered carrier-free.
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/133094
DOI of Published Version
10.1021/ACSNANO.0C03109
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.